AOD-9604: The HGH Fragment That Promised Effortless Fat Loss — and What the Trials Actually Showed

AOD-9604 arrived in the research peptide world with a compelling sales pitch: all the fat-burning benefits of human growth hormone, none of the downsides. No IGF-1 elevation. No insulin resistance. No joint swelling. Just targeted lipolysis — lipid cells broken down, new fat formation blocked, body composition quietly shifting in the right direction.

The molecule even went through legitimate clinical trials. It was taken seriously by Monash University. It received FDA GRAS designation in 2014. The origin story was credible, the early-phase data was promising, and the mechanism made elegant biological sense.

Then the Phase III trial came back, and the weight loss numbers didn't hold up against placebo.

That result did not kill AOD-9604's presence in the peptide market. If anything, it barely slowed it. Vendors still sell it. Forums still recommend 12-week cycles. Users still report results. And the cartilage repair research that emerged after the obesity program ended has given the molecule an entirely different second life in sports medicine circles.

This article gives you the full picture — mechanism, clinical history, honest evidence assessment, comparison to the GLP-1s that AOD-9604 was supposed to compete with, the ongoing cartilage research, side effects, and an honest look at the sourcing landscape. All of it, without the marketing spin.

What Is AOD-9604?

AOD-9604 — originally called "Anti-Obesity Drug 9604" — is a synthetic 16-amino-acid peptide corresponding to the C-terminal fragment of human growth hormone (hGH), specifically amino acids 176 through 191. That sequence is sometimes referenced as "hGH Fragment 176-191," which is effectively the same molecule with a slightly different name.

The story starts with a discovery made in the 1990s: that different regions of the hGH molecule do different things. The amino-terminal (N-terminal) portion of hGH drives growth — it's what activates the GH receptor, stimulates IGF-1 production, and triggers the anabolic effects that make full HGH both useful and problematic. The C-terminal fragment behaves differently. Specifically, the region around amino acids 176–191 appears to be the portion responsible for hGH's lipolytic activity — its ability to stimulate the breakdown of stored fat.

This was the insight that led Monash University researchers, led by Professor Frank Ng, to synthesize and test AOD-9604: what if you could isolate the fat-burning part of HGH and deliver it without triggering the growth-promoting, IGF-1-elevating, glucose-disrupting effects of the whole molecule?

The answer, at least biochemically, turned out to be largely yes. AOD-9604 does not bind to the primary GH receptor in a way that drives IGF-1 production. It does not meaningfully affect blood glucose or insulin sensitivity at therapeutic doses. It operates via a distinct signaling pathway — likely involving β3-adrenergic receptors and AMP-activated protein kinase (AMPK) — to stimulate lipolysis (fat breakdown) and suppress lipogenesis (new fat formation).

On paper, this was elegant. In practice, the clinical story became complicated.

The Mechanism: How AOD-9604 Is Supposed to Work

To understand what AOD-9604 does, it helps to understand what full HGH does to body fat — and why replicating just that part turned out to be harder than it looked.

Human growth hormone stimulates fat breakdown through multiple pathways. It activates hormone-sensitive lipase (HSL), the enzyme that breaks triglycerides into free fatty acids and glycerol for use as energy. It increases metabolic rate. It shifts substrate utilization toward fat oxidation, particularly during fasting and exercise. These effects are real and measurable — which is why HGH has a long history of illicit use in bodybuilding and why pharmaceutical HGH is sometimes prescribed for adult GH deficiency with documented body composition benefits.

But full HGH also raises IGF-1, which promotes cell growth (and potentially cancer cell growth). It causes water retention and joint pain. It can cause carpal tunnel syndrome. At supraphysiological doses, it induces insulin resistance. It has a black-market history, regulatory complexity, and a significant cost even at legitimate compounding pharmacies.

AOD-9604 isolates a subset of HGH's fat-metabolizing function without these broader receptor activations. The proposed mechanism involves:

• β3-adrenergic receptor stimulation — activating receptors on fat cells that trigger lipolysis, releasing stored triglycerides as free fatty acids
• AMPK activation — an energy-sensing pathway that upregulates fat oxidation and downregulates fat synthesis
• Lipogenesis inhibition — suppressing fatty acid synthase activity, reducing the formation of new fat from dietary substrates

Critically, AOD-9604 does not trigger the JAK-STAT signaling cascade associated with GH receptor activation and IGF-1 production. This has been consistently demonstrated in preclinical and clinical studies — IGF-1 levels remain stable during AOD-9604 use, which differentiates it meaningfully from HGH.

The fasted administration requirement that practitioners universally recommend follows from this mechanism: insulin blunts lipolysis. To maximize the window where AOD-9604 can stimulate fat breakdown, the metabolic environment needs to be as low-insulin as possible. This is why the standard protocol involves injecting in the morning, fasted, and avoiding food for 30–60 minutes before and after.

Clinical Trial History: The Promise and the Plateau

AOD-9604 has a more rigorous clinical development history than the vast majority of research peptides. This is important context — it went through a real pharmaceutical development program, which gives us actual data to work with, including the uncomfortable parts.

Preclinical Research

The initial preclinical work was published in the late 1990s and early 2000s. Heffernan et al. (2001) showed that AOD-9604 significantly reduced body fat in obese mice without affecting lean mass, blood glucose, or insulin. A follow-up study in β3-adrenergic receptor knockout mice demonstrated that the mechanism involved at least partially these receptors — mice lacking them showed blunted response to AOD-9604. Studies in rats showed reductions in adipose tissue mass, increases in fat oxidation rates, and no detectable effect on bone growth or IGF-1.

The animal data was genuinely compelling. Specificity of action. Meaningful effect sizes. Clean safety profile. This was the foundation that justified advancing to human trials.

Phase I and Phase II Trials

Phase I studies established that AOD-9604 was well-tolerated in humans across a dose range from 25 mcg to 400 mcg administered orally and via injection. No serious adverse events. No IGF-1 elevation. No glucose disruption. The safety profile was exactly what the preclinical work had predicted.

Phase II trials — the first real tests of efficacy in humans — produced the results that gave the peptide its commercial momentum. Stier et al. (2013) and related publications reported modest but statistically significant weight loss versus placebo at oral doses of 1–9 mg/day over 12-week trials. The injectable form was less studied in formal trials but was simultaneously gaining traction in the research peptide market based on the oral pharmacology extrapolated to subcutaneous use.

Key Phase II findings:

• Weight loss of approximately 2–3 kg versus placebo over 12 weeks at optimal doses
• No significant changes in IGF-1, blood glucose, or insulin sensitivity
• No dose-limiting toxicity up to 9 mg/day oral
• GRAS (Generally Recognized as Safe) application submitted and ultimately granted by FDA (2014) for use as a food ingredient

The Phase II results were modest — 2–3 kg over 12 weeks is not dramatic — but they were consistent and statistically significant. Enough to justify advancing to Phase III.

Phase III: The Failure

The Phase III program involved approximately 700 participants across multiple sites, with longer treatment durations and more rigorous primary endpoints. The trial used oral AOD-9604 at the dose range that had shown effect in Phase II.

The primary outcome — statistically significant weight loss versus placebo — was not achieved.

This was a decisive failure. Phase III failure means the molecule could not demonstrate sufficient efficacy at the tested doses in the tested population to warrant regulatory approval as an obesity drug. Metabolic Pharmaceuticals (the commercial developer) subsequently ended the obesity indication development program.

Several factors have been proposed to explain the Phase III failure:

• Dose optimization issues — oral bioavailability is variable; the therapeutic dose in a larger, more heterogeneous population may differ from Phase II
• Population size and variance — larger trials detect true but smaller effect sizes; the Phase II effect may have been real but too small to survive Phase III variance
• Route of administration — all Phase II and III trials used oral dosing; injectable AOD-9604 has never been formally validated in a Phase III trial
• Regulatory endpoint stringency — Phase III obesity endpoints require clinically meaningful weight loss (typically ≥5% body weight), which may simply be beyond what AOD-9604 can reliably deliver

The honest interpretation: AOD-9604 probably does something, at the biochemical level, that involves fat metabolism. But as a standalone obesity intervention, the effect size is insufficient to meet pharmaceutical-grade efficacy standards. This is a real finding that should temper expectations — not a reason to dismiss the molecule entirely, but an important calibration.

Honest Evidence Assessment: What We Know, What We Don't

Where does AOD-9604 actually stand in 2026?

What the evidence supports:

• AOD-9604 stimulates lipolysis in preclinical models via a distinct receptor pathway from full HGH
• It does not raise IGF-1, affect blood glucose, or impair insulin sensitivity at studied doses
• Short-term human safety is well-established — better documented than most research peptides
• Phase II trials showed modest weight loss (2–3 kg) over 12 weeks with oral administration
• FDA GRAS designation confirms short-term oral safety at the food ingredient level

What the evidence does not support:

• Dramatic or reliable fat loss as a standalone intervention — Phase III failed
• Efficacy of injectable vs. oral routes (no direct comparative trials exist)
• Long-term injectable safety (no formal data)
• Specific dosing protocols for the injectable form used in the research peptide market (all trial data is from oral dosing)
• Synergistic effect sizes when stacked with CJC-1295/Ipamorelin (theorized, not studied)

The peptide market's enthusiasm for AOD-9604 injectable protocols (300–600 mcg/day SC) is based on mechanistic logic, not controlled injectable trial data. Users report anecdotal results. Some of that is likely real — the mechanism is credible — but the effect size in people with controlled diets is probably modest, and the injectable dose-response relationship is essentially unknown.

AOD-9604 vs. GLP-1 Agonists: A Realistic Comparison

If you are considering AOD-9604 for fat loss in 2026, the most important context is the comparison to semaglutide and tirzepatide — the GLP-1 and GLP-1/GIP receptor agonists that now dominate the evidence-based weight loss landscape.

The comparison is not kind to AOD-9604, and you should understand why.

If your goal is meaningful weight loss — 10%, 15%, 20%+ of body weight — AOD-9604 is not a realistic primary tool. The GLP-1 agonists have a level of clinical evidence that AOD-9604's program did not achieve, and the effect size difference is enormous.

Where AOD-9604 makes more sense as a consideration:

• People who cannot or choose not to use GLP-1 agonists (cost, side effects, prescriber access)
• Those already in a significant caloric deficit looking to incrementally support fat oxidation
• Athletes or body composition-focused users aiming to reduce body fat percentage without aggressive pharmaceutical intervention
• Stacking as a complementary compound alongside CJC-1295/Ipamorelin in a GH optimization protocol

The honest framing: AOD-9604 may do something modest and real for fat metabolism in the right context. It will not rescue a poor diet or match the outcomes of a GLP-1 agonist. Use it with accurate expectations.

The Second Act: Cartilage Repair Research

After the obesity program ended, the research on AOD-9604 did not simply stop. A separate line of investigation had been developing — and it points toward a potentially more viable application: cartilage and joint repair.

The same team that developed AOD-9604 for obesity, working through Heptagen and subsequently Fidia Farmaceutici, pivoted to studying the molecule's effects on chondrocytes (cartilage cells) and joint tissue. The underlying rationale: hGH and its fragments have known anabolic effects on cartilage and connective tissue, and the lipolytic fragment may carry some of these properties without the systemic growth-promoting concerns of full HGH.

A series of in vitro and animal studies (2010–2022) showed:

• AOD-9604 stimulates chondrocyte proliferation and proteoglycan synthesis in culture
• Intra-articular injection of AOD-9604 reduced cartilage degradation in rat osteoarthritis models
• The molecule appears to modulate pathways relevant to cartilage matrix production (TGF-β, collagen type II expression)
• Safety profile in joint injection models was favorable — no inflammatory reactions, no systemic effects

As of 2024–2026, AOD-9604 for osteoarthritis (OA) was in clinical investigation under the brand name "Tregopil" — though it's worth noting that "Tregopil" has been used for multiple compounds and the regulatory landscape is complex. The more accurate framing is that AOD-9604 intra-articular injection was in various stages of preclinical and early clinical investigation for OA, with more active development in Australia and parts of Europe than in the US.

This cartilage research has increased AOD-9604's visibility in the sports medicine and anti-aging peptide community — often stacked with BPC-157 for joint recovery protocols. The evidence base for this application is considerably earlier-stage than the obesity data, but the mechanistic rationale is credible and the preliminary data is more promising than the Phase III obesity result.

Stacking with CJC-1295 and Ipamorelin

The most commonly discussed AOD-9604 stack in research peptide circles pairs it with CJC-1295 (no DAC) and Ipamorelin — the growth hormone secretagogue combination that drives pulsatile GH release. See the Protocols Hub for full dosing details on this combination.

The theoretical rationale for this stack:

• CJC-1295 + Ipamorelin increase endogenous GH pulsatility, which supports overall body composition (muscle-to-fat ratio), sleep quality, and recovery
• AOD-9604 provides direct lipolytic stimulation on fat cells, operating via a pathway that does not depend on elevated GH or IGF-1 levels
• The combination theoretically produces complementary effects: GH secretagogues working on the systemic axis, AOD-9604 working directly at the fat cell

Standard practice for this stack:

• AOD-9604: 300 mcg SC fasted AM (minimum 2–3 hours since last meal)
• CJC-1295 (no DAC): 100 mcg SC + Ipamorelin 100 mcg SC, administered pre-sleep (to align with the natural overnight GH pulse)
• Cycle length: 12–16 weeks on, 4–8 weeks off

Important caveats: this specific combination has not been tested in any clinical trial. The synergy is theoretical. Individual responses vary. The GH secretagogue components (CJC-1295, Ipamorelin) have more clinical evidence individually than AOD-9604 does at this point — if resources are limited, prioritizing the secretagogues alone may deliver more reliable benefit. See our CJC-1295/Ipamorelin profile for evidence details.

Dosing and Administration

All published AOD-9604 clinical trial data was obtained using oral administration. The injectable protocols used in the research peptide market are extrapolations — the dose-response relationship for subcutaneous AOD-9604 is not established by formal trial data.

Common injectable protocols (based on market convention, not clinical validation):

• Standard dose: 300 mcg SC once daily, fasted AM
• Split dose: 300 mcg fasted AM + 300 mcg pre-workout (fasted or 3+ hours post-meal)
• Cycle duration: 12–16 weeks, followed by 4–8 weeks off
• Administration site: Abdomen (subcutaneous), rotating sites
• Reconstitution: Standard bacteriostatic water; 1–3 mg vials are common. Use the WellSourced Peptide Calculator for exact reconstitution math

The fasted requirement is the single most important protocol consideration. Insulin opposes lipolysis. Elevated insulin from a recent meal will blunt AOD-9604's intended mechanism. Morning fasted injection — before coffee with cream, before breakfast — is standard practice for good biochemical reasons.

Storage: refrigerate at 2–8°C after reconstitution. Use within 28–30 days of reconstitution.

Side Effects and Safety Profile

AOD-9604 has a well-characterized short-term safety profile — better than almost any other research peptide, precisely because it went through a formal clinical development program with safety monitoring.

Documented in clinical trials (oral administration):

• No significant adverse events across Phase I, II, or Phase III programs
• No IGF-1 elevation at any tested dose
• No impact on fasting glucose, HbA1c, or insulin sensitivity
• No effect on bone density, growth, or organ size
• FDA GRAS status (food ingredient level) — short-term oral safety established

Anecdotally reported with injectable use:

• Injection site redness or mild bruising (common with any SC peptide)
• Transient nausea (uncommon; typically dose-dependent)
• Headache (rare)
• Flushing (rare)

What AOD-9604 does NOT cause (unlike full HGH):

• Water retention or "HGH gut"
• Joint pain (HGH commonly causes joint and carpal tunnel-like symptoms)
• IGF-1-driven growth stimulation (no theoretical cancer promotion concern at this dose)
• Blood glucose disruption or insulin resistance
• Acromegaly-related effects

The safety advantage over full HGH is real and meaningful. That said: long-term injectable safety data does not exist. The clinical trials used oral dosing for ≤12 weeks. Multi-year injectable use has not been formally studied in any population. Anyone using AOD-9604 injections long-term is extrapolating from shorter-duration oral data — a meaningful knowledge gap.

The Sourcing Landscape

AOD-9604 is widely available from research peptide vendors. It is not a scheduled substance in most jurisdictions, is not FDA-approved, and occupies a regulatory grey area as a "research chemical" not approved for human use.

Sourcing considerations:

• Quality variance is significant. The research peptide market is unregulated. Third-party testing (HPLC purity, mass spectrometry) is the only way to verify what is in a vial. Vendors who publish independent CoAs (Certificates of Analysis) from accredited labs are preferable to those who do not.
• Concentration matters. Vials are commonly sold as 1 mg, 2 mg, or 5 mg of lyophilized peptide. Reconstitution volume determines the concentration and therefore the injection volume. Use the Reconstitution Calculator before injecting.
• Fakes are common. Some vendors sell degraded, mislabeled, or outright counterfeit peptides. Price is not a reliable quality indicator. Community reputation, independent lab results, and vendor longevity matter more.
• Legal status varies by country. In the US, AOD-9604 is not scheduled and not a controlled substance, but it is also not approved for human administration. In Australia (where it was developed), it has had a more complex regulatory history. Check your local jurisdiction before purchasing.

WellSourced does not endorse specific vendors. If you choose to purchase research peptides, prioritize vendors who provide independently verified purity certificates from accredited analytical labs, not just in-house documentation. The Our Picks section covers sourcing criteria in more detail.

The Bottom Line on AOD-9604

AOD-9604 is one of the more interesting research peptides in the fat loss category — not because it is particularly effective, but because it has a more credible development history than most, and because its honest story is more useful than the marketing version.

The marketing version: it burns fat without any HGH side effects and will reshape your body composition in 12 weeks.

The honest version: it probably does something real at the biochemical level, with a favorable safety profile. The Phase II oral trial results were modest. The Phase III injectable extrapolation has not been formally validated. It will not produce the weight loss of a GLP-1 agonist. It may have a legitimate future in joint and cartilage medicine that is distinct from its original obesity indication.

If you are managing clinically significant obesity, the evidence-based options are semaglutide, tirzepatide, and lifestyle interventions — full stop. Those tools have Phase III data. They have FDA approvals. They work.

If you are managing incremental body composition changes in an already healthy range, operating within a meaningful caloric deficit, and looking for a research compound with a reasonable safety profile to potentially complement your protocol — AOD-9604 is a more defensible choice than most of what the peptide market offers. Just hold your expectations appropriately, dose fasted, and use it as one tool in a system that starts with diet and training.